Rethinking classification and categorization of resection extent and its impact on patient survival in glioblastoma: Was Walter Dandy ahead of his time?
- PMID: 36645373
- PMCID: PMC10158154
- DOI: 10.1093/neuonc/noad013
Rethinking classification and categorization of resection extent and its impact on patient survival in glioblastoma: Was Walter Dandy ahead of his time?
Conflict of interest statement
The text is solely the product of the authors and no third party had input or gave support to its writing. RK: Consulting Fees and honoraria from Accuray Inc., Elekta AB, ViewRay Inc., Novocure Inc., Elsevier Inc., Brainlab, Kazia Therapeutics, Castle Biosciences, and institutional research funding from Medtronic Inc., Blue Earth Diagnostics Ltd., Novocure Inc., GT Medical Technologies, AstraZeneca, Exelixis, ViewRay Inc., Brainlab, Cantex Pharmaceuticals, and Kazia Therapeutics. M.P.M: Consulting Fees from Kazia Therapeutics, Karyopharm, Sapience, Zap, Mevion, Xoft; BOD Oncoceutics; Stock in Chimerix
Figures

Comment on
-
Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group.Neuro Oncol. 2023 May 4;25(5):940-954. doi: 10.1093/neuonc/noac193. Neuro Oncol. 2023. PMID: 35961053 Free PMC article.
References
-
- Dandy WE. Removal of right cerebral hemisphere for certain tumors with hemiplegia: preliminary report. J. Am. Med. Assoc. 1928;90(11):823–825.
-
- Karschnia P, Vogelbaum MA, van den Bent M, et al. . Evidence-based recommendations on categories for extent of resection in diffuse glioma. Eur J Cancer. 2021;149(91):23–33. - PubMed